Sunitinib monotherapy in a patient with primary breast cancer

详细信息    查看全文

• 作者：Hitomi Sumiyoshi (1)
  Tomoyuki Aruga (1)
  Hiromi Miyamoto (1)
  Junko Ishiguro (1)
  Yayoi Honda (1)
  Takashi Shigekawa (1)
  Dai Kitagawa (1)
  Kazumi Horiguchi (1)
  Toshinari Yamashita (1)
  Shinichiro Horiguchi (2)
  Katsumasa Kuroi (1)
  
• 关键词：Sunitinib ; Antiangiogenic therapy ; Early ; stage breast cancer ; Luminal breast cancer ; Synchronous malignancy
• 刊名：International Cancer Conference Journal
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：3
• 期：2
• 页码：91-95
• 全文大小：
• 参考文献：1. Matsuda A, Matsuda T, Shibata A et al (2013) Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 43(3):328鈥?36 CrossRef
  2. Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810鈥?816 CrossRef
  3. Bergh J, Bondarenko IM, Lichinitser MR et al (2010) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30:921鈥?29 CrossRef
  4. Crown J, Dieras V, Straroslawska E et al (2010) Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 28:18s (suppl; abstr LBA1011)
  5. Barrios C, Liu MC, Lee S et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121鈥?31 CrossRef
  6. Robert NJ, Saleh MN, Paul D et al (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11:82鈥?2 CrossRef
  7. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327鈥?37
  8. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971鈥?79 CrossRef
  9. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115鈥?24 CrossRef
  10. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329鈥?338 CrossRef
  11. The ATAC Trialists鈥?Group, Forbes JF, Cuzick J et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100聽month analysis of the ATAC trial. Lancet Oncol 9:45鈥?3 CrossRef
  12. Ferrara N, Gerber HP, LeCouter J (2003) The biological properties of VEGF and its receptors. Nat Med 9:669鈥?76 CrossRef
  13. Toi M, Inada K, Hoshina S et al (1995) Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1:961鈥?64
  14. Gasparini G, Bonokli E, Gatti C et al (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2):139鈥?47 CrossRef
  15. Young E, Miele L, Tucker KB et al (2010) SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. Cancer Biol Ther 10:703鈥?11 CrossRef
  16. Miller K, Estes M, Perkins S et al (2009) An exploratory study of the biological activity of sunitinib as a component of neoadjuvant therapy for breast cancer. Cancer Res. 69:24 Suppl (abstract nr 202)
  17. Keyvanjah K, DePrimo SE, Harmon CS et al (2012) Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib. J Transl Med 10:165. doi:10.1186/1479-5876-10-165 CrossRef
  18. Brown LF, Berse B, Jackman RW et al (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86鈥?1 CrossRef
  19. Liu Y, Tamimi RM, Collins LC et al (2011) The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses鈥?Health Study. Breast Cancer Res Treat 129:175鈥?84
  
• 作者单位：Hitomi Sumiyoshi (1)
  Tomoyuki Aruga (1)
  Hiromi Miyamoto (1)
  Junko Ishiguro (1)
  Yayoi Honda (1)
  Takashi Shigekawa (1)
  Dai Kitagawa (1)
  Kazumi Horiguchi (1)
  Toshinari Yamashita (1)
  Shinichiro Horiguchi (2)
  Katsumasa Kuroi (1)
  
  1. Departments of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-0021, Japan
  2. Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-0021, Japan
  
• ISSN：2192-3183

文摘

Sunitinib is an oral multi-targeted tyrosine kinase inhibitor approved for use in patients with advanced renal cell carcinoma (RCC). However, despite its preclinical biological effect on breast cancer, it is yet to be proven effective for clinical use in patients with breast cancer. The present report describes a case of a 69-year-old woman with advanced clear-cell RCC and a luminal B subtype invasive ductal carcinoma of the right breast that showed a partial response to monotherapy with sunitinib. This is the first report of the effect of sunitinib monotherapy in a patient with early-stage breast cancer.